Should I buy or sell Zura Bio stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZURA shares. View ZURA analyst ratings or view top-rated stocks .

What is Zura Bio's stock price target for 2024?

5 analysts have issued 12-month price objectives for Zura Bio's shares. Their ZURA share price targets range from $10.00 to $22.00. On average, they anticipate the company's share price to reach $16.60 in the next year. This suggests a possible upside of 316.0% from the stock's current price. View analysts price targets for ZURA or view top-rated stocks among Wall Street analysts .

How have ZURA shares performed in 2023?

Zura Bio's stock was trading at $29.42 at the start of the year. Since then, ZURA stock has decreased by 86.4% and is now trading at $3.99. View the best growth stocks for 2023 here .

Are investors shorting Zura Bio?

Zura Bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 171,200 shares, a decrease of 62.9% from the October 31st total of 461,900 shares. Based on an average trading volume of 129,700 shares, the short-interest ratio is presently 1.3 days. Currently, 0.8% of the company's stock are short sold. View Zura Bio's Short Interest .

When is Zura Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our ZURA earnings forecast .

How were Zura Bio's earnings last quarter?

Zura Bio Limited (NASDAQ:ZURA) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07.

Who are Zura Bio's major shareholders?

Zura Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (3.67%), Silverarc Capital Management LLC (0.94%), Invesco Ltd. (0.27%), Eisler Capital US LLC (0.23%), Northern Trust Corp (0.22%) and Charles Schwab Investment Management Inc. (0.22%). View institutional ownership trends .

How do I buy shares of Zura Bio?

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Zura Bio Stock Price, News & Analysis (NASDAQ:ZURA)

$3.99

-0.03 (-0.75%)

(As of 11:37 AM ET)

Compare

Today's Range: $3.92
▼
$4.07
50-Day Range: $4.00
▼
$7.00
52-Week Range: $3.91
▼
$37.55

Volume: 46,423 shs
Average Volume: 315,813 shs
Market Capitalization: $171.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.60

Zura Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.20 Rating Score
Upside/Downside: 316.0% Upside
$16.60 Price Target
Short Interest: Healthy
0.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.74) to ($0.98) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

298th out of 958 stocks

Biological Products, Except Diagnostic Industry

44th out of 146 stocks

3.6

Analyst's Opinion

Consensus Rating
Zura Bio has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.60, Zura Bio has a forecasted upside of 316.0% from its current price of $3.99.
Amount of Analyst Coverage
Zura Bio has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.83% of the float of Zura Bio has been sold short.
Short Interest Ratio / Days to Cover
Zura Bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zura Bio has recently decreased by 62.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Zura Bio does not currently pay a dividend.
Dividend Growth
Zura Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZURA.

2.4

News and Social Media Coverage

News Sentiment
Zura Bio has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Zura Bio this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for ZURA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
4 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zura Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.80% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zura Bio are expected to grow in the coming year, from ($2.74) to ($0.98) per share.

See Top Rated MarketRank™ Stocks Here

About Zura Bio Stock (NASDAQ:ZURA)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

ZURA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZURA Stock News Headlines

December 4, 2023 | finance.yahoo.com

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

November 30, 2023 | americanbankingnews.com

Short Interest in Zura Bio Limited (NASDAQ:ZURA) Decreases By 62.9%

December 7, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.

November 14, 2023 | finance.yahoo.com

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

November 13, 2023 | msn.com

Zura Bio GAAP EPS of -$0.18

November 13, 2023 | finance.yahoo.com

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

October 11, 2023 | msn.com

Ladenburg Thalmann Initiates Coverage of Zura Bio Ltd - (ZURA) with Buy Recommendation

September 12, 2023 | finance.yahoo.com

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

December 7, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

September 7, 2023 | barrons.com

Zura Bio Ltd. Wt

September 7, 2023 | finance.yahoo.com

We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely

August 25, 2023 | msn.com

Oppenheimer starts Zura Bio at outperform, cites potential of ZB-106

August 25, 2023 | msn.com

Oppenheimer Initiates Coverage of Zura Bio Ltd - (ZURA) with Outperform Recommendation

August 15, 2023 | msn.com

Raymond James Maintains Zura Bio Ltd - (ZURA) Strong Buy Recommendation

August 15, 2023 | markets.businessinsider.com

Where Zura Bio Stands With Analysts

August 14, 2023 | finance.yahoo.com

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

July 20, 2023 | seekingalpha.com

ZURAW Zura Bio Limited WT EXP 032028

June 23, 2023 | benzinga.com

Zura Bio shares are trading lower Wednesday amid possible profit-taking after the stock rallied on Tuesday.

June 23, 2023 | seekingalpha.com

Zura Bio to join Russell 2000 and Russell 3000 indexes

June 23, 2023 | benzinga.com

Zura Bio shares are trading higher after the company announced it will join the Russell 2000 and Russell 3000 indexes.

June 22, 2023 | seekingalpha.com

Zura Bio a new buy at Guggenheim on immunology, inflammation assets

June 22, 2023 | investing.com

Zura Bio Ltd (94E)

June 21, 2023 | fool.com

Zura Bio (NASDAQ: ZURA)

June 21, 2023 | markets.businessinsider.com

What's Going On With Zura Bio Stock Today

June 20, 2023 | fool.com

Why Shares of Zura Bio Climbed Tuesday

June 14, 2023 | benzinga.com

Chardan Capital Initiates Coverage On Zura Bio with Buy Rating, Announces Price Target of $14

June 6, 2023 | investorplace.com

Why Is Zura Bio (ZURA) Stock Up 9% Today?

See More Headlines

Receive ZURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZURA
CUSIP: N/A
CIK: 1855644
Web: N/A
Phone: 858-247-0520
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.60
High Stock Price Target: $22.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +312.9%
Consensus Rating: Buy
Rating Score (0-4): 3.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $3.55 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -74.71%
Return on Assets: -38.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.15
Quick Ratio: 6.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: $0.86 per share
Price / Cash Flow: 4.65
Book Value: ($2.21) per share
Price / Book: -1.82

Miscellaneous

Outstanding Shares: 43,090,000
Free Float: 36,285,000
Market Cap: $173.22 million
Optionable: Not Optionable
Beta: 0.54

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. David Brady
Head of Business Development
Dr. Someit Sidhu M.D. (Age 34)
CEO & Director
Mr. Verender S. Badial (Age 51)
Chief Financial Officer
Dr. Gary Whale (Age 49)
Chief Technology Officer
Dr. Michael D. Howell Ph.D. (Age 46)
Chief Scientific Officer & Head of Translational Science
Ms. Kimberly Ann Davis (Age 55)
Chief Legal Officer & Secretary
Ms. Theresa Lowry (Age 49)
Chief Human Resources Officer
Dr. Christopher H. Cabell FACC (Age 54)
M.D., MHS, Chief Medical Officer, Executive VP and Head of R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Zura Bio stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZURA shares.
View ZURA analyst ratings or view top-rated stocks.
What is Zura Bio's stock price target for 2024?: 5 analysts have issued 12-month price objectives for Zura Bio's shares. Their ZURA share price targets range from $10.00 to $22.00. On average, they anticipate the company's share price to reach $16.60 in the next year. This suggests a possible upside of 316.0% from the stock's current price.
View analysts price targets for ZURA or view top-rated stocks among Wall Street analysts.
How have ZURA shares performed in 2023?: Zura Bio's stock was trading at $29.42 at the start of the year. Since then, ZURA stock has decreased by 86.4% and is now trading at $3.99.
View the best growth stocks for 2023 here.
Are investors shorting Zura Bio?: Zura Bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 171,200 shares, a decrease of 62.9% from the October 31st total of 461,900 shares. Based on an average trading volume of 129,700 shares, the short-interest ratio is presently 1.3 days. Currently, 0.8% of the company's stock are short sold.
View Zura Bio's Short Interest.

When is Zura Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our ZURA earnings forecast.
How were Zura Bio's earnings last quarter?: Zura Bio Limited (NASDAQ:ZURA) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07.
Who are Zura Bio's major shareholders?: Zura Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (3.67%), Silverarc Capital Management LLC (0.94%), Invesco Ltd. (0.27%), Eisler Capital US LLC (0.23%), Northern Trust Corp (0.22%) and Charles Schwab Investment Management Inc. (0.22%).
View institutional ownership trends.
How do I buy shares of Zura Bio?: Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ZURA) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial